Skip to main content
Premium Trial:

Request an Annual Quote

TherImmune Helps Gene Logic Buoy Q4 Revenue

NEW YORK, Feb. 20 (GenomeWeb News) - Gene Logic reported an increase in total fourth-quarter revehue, but if the company hadn't acquired TherImmune Research, its revenues would have fallen around $1 million.

 

Revenues for the three months ended Dec. 31 increased to $19.7 million from $14.8 million one year ago largely on the shoulders of the $5.8 million generated by TherImmune Research, which Gene Logic acquired last April. Without the acquiaition, Gene Logi's revenue for the fourth quarter 2003 would have been $13.9 million compared with $14.8 million for the same period one year ago.

 

R&D costs decreased to $500,000 from $800,000 during the same quarter a year ago, while net loss decreased to $4.9 million, or $.16 per share, from $5.2 million, or $.19 per share, during the fourth quarter a year ago.

 

As of Dec. 31, Gene Logic had approximately $111.8 million in cash, cash equivalents and marketable securities available-for-sale. This includes $48.7 million in cash and cash equivalents.

 

Click here for the full earnings report.

 

Separately, Gene Logic said that Boehringer Ingelheim has renewed its license to Gene Logic's GeneExpress information services for several years.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.